WTI Generics 1 Practice Test

Interchangeability for generic small-molecule drugs hinges on showing bioequivalence and therapeutic equivalence. When a generic product is demonstrated to be bioequivalent to the reference drug and is deemed therapeutically equivalent, pharmacists can substitute it for the brand-name product in many settings. This practical substitution is guided by BE (bioequivalence) and TE (therapeutic equivalence) assessments, and the AB-rated designation in the FDA’s Orange Book signals that a generic is interchangeable with the reference drug and commonly substituted in practice. The formal interchangeability label is a concept used mainly for biologics (biosimilars), requiring additional data to prove substitution without the prescriber’s input. So, BE and TE support substitution, AB-rated generics are commonly substituted, and there isn’t a separate small-molecule “interchangeability” designation used in the same way as for biologics. The other statements misstate the reality of substitution: pharmacists do substitute generics under appropriate rules, and not all generics are automatically interchangeable without the AB rating or equivalent evidence.